// App-Quantinova.ai

5353 : PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC

Researchers

Presenter

  • Ursula Grazini

Principal Investigators

  • Daniel J. O'Neill

  • Matthew Martin

  • Chintia Xu

  • Nicolas Floch

  • Paul D. Smith

  • Emanuela Cuomo

Medical Centers

  • Astra Zeneca, Cambridge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • Mitogen-activated protein kinase

  • Nucleoside diphosphate kinase A

  • Phosphorylated-AKT

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • PI3K/AKT

  • Circulating DNA

Drug/Treatment

  • Tagrisso

  • Alpelisib

  • AZD-8186

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved